Search Results - "Franco, Lori"

Refine Results
  1. 1

    Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients by De Forni, Davide, Poddesu, Barbara, Cugia, Giulia, Chafouleas, James, Lisziewicz, Julianna, Lori, Franco

    Published in PloS one (10-11-2022)
    “…Despite new antivirals are being approved against SARS-CoV-2 they suffer from significant constraints and are not indicated for hospitalized patients, who are…”
    Get full text
    Journal Article
  2. 2

    Visible Light Activation of Virucidal Surfaces Empowered by Pro‐Oxidant Carbon Dots by Malfatti, Luca, Poddighe, Matteo, Stagi, Luigi, Carboni, Davide, Anedda, Roberto, Casula, Maria Francesca, Poddesu, Barbara, De Forni, Davide, Lori, Franco, Livraghi, Stefano, Zollo, Alessia, Calvillo, Laura, Innocenzi, Plinio

    Published in Advanced functional materials (01-11-2024)
    “…The scientific community is actively engaged in the development of innovative nanomaterials with broad‐spectrum virucidal properties, particularly those…”
    Get full text
    Journal Article
  3. 3

    SARS-CoV-2 Inactivation in Aerosol by Means of Radiated Microwaves by Manna, Antonio, De Forni, Davide, Bartocci, Marco, Pasculli, Nicola, Poddesu, Barbara, Lista, Florigio, De Santis, Riccardo, Amatore, Donatella, Grilli, Giorgia, Molinari, Filippo, Sangiovanni Vincentelli, Alberto, Lori, Franco

    Published in Viruses (27-06-2023)
    “…Coronaviruses are a family of viruses that cause disease in mammals and birds. In humans, coronaviruses cause infections on the respiratory tract that can be…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Precision COVID-19 Vaccine with Companion Diagnostics by Lisziewicz, Julianna, Lori, Franco

    Published in Precision nanomedicine (10-04-2020)
    “…<img src=” https://s3.amazonaws.com/production.scholastica/article/12561/medium/prnano_412020_figure_1.jpg?1586516744”> Although disease enhancement by…”
    Get full text
    Journal Article
  6. 6

    Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals by Lisziewicz, Julianna, Bakare, Nyasha, Calarota, Sandra A, Bánhegyi, Dénes, Szlávik, János, Ujhelyi, Eszter, Tőke, Enikő R, Molnár, Levente, Lisziewicz, Zsolt, Autran, Brigitte, Lori, Franco

    Published in PloS one (09-05-2012)
    “…The GIHU004 study was designed to evaluate the safety and immunogenicity of three doses of DermaVir immunization in HIV-infected subjects on fully suppressive…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Structured Treatment Interruptions for the Management of HIV Infection by Lori, Franco, Lisziewicz, Julianna

    “…Antiretroviral drugs constitute a milestone in the treatment of human immunodeficiency virus (HIV) infection; however, emerging problems limit their long-term…”
    Get full text
    Journal Article
  9. 9

    ViroStatics Testing Capabilities to Determine Efficacy of Drugs, Disinfectants or Devices against SARS-CoV-2 by Poddesu, Barbara, Cugia, Giulia, Lori, Franco, De Forni, Davide

    Published in Precision nanomedicine (27-06-2021)
    “…ViroStatics is a privately held small pharmaceutical company dedicated to discovering and developing novel compounds for a multifaceted treatment of cancers…”
    Get full text
    Journal Article
  10. 10

    VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics by Lori, Franco, De Forni, Davide, Katabira, Elly, Baev, Denis, Maserati, Renato, Calarota, Sandra A, Cahn, Pedro, Testori, Marco, Rakhmanova, Aza, Stevens, Michael R

    Published in PloS one (19-10-2012)
    “…A new class of antiretrovirals, AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs), has been proposed as a disease-modifying therapy to both reduce…”
    Get full text
    Journal Article
  11. 11

    DermaVir: A Novel Topical Vaccine for HIV/AIDS by Lisziewicz, Julianna, Trocio, Jeffrey, Whitman, Lucia, Varga, Georg, Xu, Jianqing, Bakare, Nyasha, Erbacher, Patrick, Fox, Cecil, Woodward, Ruth, Markham, Phil, Arya, Suresh, Behr, Jean-Paul, Lori, Franco

    Published in Journal of investigative dermatology (01-01-2005)
    “…Human immunodeficiency virus (HIV) vaccines have the potential to improve antiretroviral drug treatment by inducing cytotoxic killing of HIV-infected cells…”
    Get full text
    Journal Article
  12. 12

    Control of SIV Rebound through Structured Treatment Interruptions during Early Infection by Lori, Franco, Lewis, Mark G., Xu, Jianqing, Varga, Georg, Zinn, Donald E., Crabbs, Carrol, Wagner, Wendeline, Greenhouse, Jack, Silvera, Peter, Yalley-Ogunro, Jake, Tinelli, Carmine, Lisziewicz, Julianna

    “…In a randomized controlled trial with acute simian immunodeficiency virus (SIV)-infected macaques, both highly active antiretroviral therapy (HAART) and HAART…”
    Get full text
    Journal Article
  13. 13

    Beneficial effect of TRAIL on HIV burden, without detectable immune consequences by Shepard, Brett D, De Forni, Davide, McNamara, David R, Foli, Andrea, Rizza, Stacey A, Abraham, Roshini S, Knutson, Keith, Wettstein, Peter J, Lori, Franco, Badley, Andrew D

    Published in PloS one (28-08-2008)
    “…During uncontrolled HIV disease, both TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptor expression are increased. Enhanced TRAIL sensitivity is…”
    Get full text
    Journal Article
  14. 14

    Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication by Lori, Franco, Malykh, Andrei, Cara, Andrea, Sun, Daisy, Weinstein, John N., Lisziewicz, Julianna, Gallo, Robert C.

    “…Hydroxyurea, a drug widely used in therapy of several human diseases, inhibits deoxynucleotide synthesis-and, consequently, DNA synthesis-by blocking the…”
    Get full text
    Journal Article
  15. 15

    Low Levels of Deoxynucleotides in Peripheral Blood Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type 1 Replication by WEN-YI GAO, CARA, A, GALLO, R. C, LORI, F

    “…Human immunodeficiency virus type 1 (HIV-1) viral DNA synthesis in quiescent and activated peripheral blood lymphocytes (PBLs) was studied. Incomplete viral…”
    Get full text
    Journal Article
  16. 16

    Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects by Lori, Franco, Foli, Andrea, Lisziewicz, Julianna

    Published in Journal of antimicrobial chemotherapy (01-08-2002)
    “…Highly active antiretroviral therapy (HAART) allows for substantial control of HIV replication in vivo, and has caused a significant decline in morbidity and…”
    Get full text
    Journal Article
  17. 17

    Mutations in the pol Gene of Human Immunodeficiency Virus Type 1 in Infected Patients Receiving Didanosine and Hydroxyurea Combination Therapy by Antoni, Anna De, Foli, Andrea, Lisziewicz, Julianna, Lori, Franco

    Published in The Journal of infectious diseases (01-10-1997)
    “…The pattern of mutations in the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) strains that confer resistance to didanosine (ddI)…”
    Get full text
    Journal Article
  18. 18

    DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS by Lori, Franco

    Published in Expert review of vaccines (01-10-2011)
    “…The HIV global pandemic continues to rage with over 33 million people living with the disease. Although multidrug therapy has improved the prognosis for those…”
    Get more information
    Journal Article
  19. 19

    CD4^+ T cell-mediated presentation of non-infectious HIV-1 virion antigens to HIV-specific CD8^+ T cells by Xu, Jian-qing, Lori, Franco, Lisziewicz, Julianna

    Published in Chinese medical journal (05-10-2006)
    “…Background The mechanism of chronic immune activation and impairment of HIV-specific immune responses during chronic infection is not fully understood…”
    Get full text
    Journal Article
  20. 20

    Induction of Potent Human Immunodeficiency Virus Type 1-Specific T-Cell-Restricted Immunity by Genetically Modified Dendritic Cells by Lisziewicz, J, Gabrilovich, D I, Varga, G, Xu, J, Greenberg, P D, Arya, S K, Bosch, M, Behr, J P, Lori, F

    Published in Journal of Virology (01-08-2001)
    “…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
    Get full text
    Journal Article